OCTANATE 100 UI/ml, poudre et solvant pour solution injectable ( DrugBank: Octanate )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 288 | Autoimmune acquired coagulation factor deficiency | 1 |
288. Autoimmune acquired coagulation factor deficiency
Clinical trials : 205 / Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-004435-22-FR (EUCTR) | 01/09/2007 | 27/03/2007 | Incidence of inhibitors in previously untreated patient with severe haemophilia A treated with Octanate (Phase III) - Etude AVI 4-03 | Incidence of inhibitors in previously untreated patient with severe haemophilia A treated with Octanate (Phase III) - Etude AVI 4-03 | Hémophilie A sévère MedDRA version: 9.1;Level: LLT;Classification code 10018937;Term: Haemophilia A MedDRA version: 9.1;Classification code 10060612;Term: Hemophilia A MedDRA version: 9.1;Level: PT;Classification code 10016080;Term: Factor VIII deficiency MedDRA version: 9.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders | Trade Name: OCTANATE 50 UI/ml, poudre et solvant pour solution injectable Trade Name: OCTANATE 100 UI/ml, poudre et solvant pour solution injectable | OCTAPHARMA AG | NULL | Not Recruiting | Female: yes Male: yes | 35 | Phase 3 | Czech Republic;France |